Xenios AG

Xenios AG is a German medical device company headquartered in Heilbronn, Baden-Wuerttemberg, that specializes in extracorporeal membrane oxygenation (ECMO) and extracorporeal life support (ECLS) technologies for critically ill patients suffering from cardiac and/or pulmonary failure. The company develops and manufactures hardware and disposables that combine both heart and lung support on a single technological platform, the Xenios console, which supports gas exchange in the lungs and the cardiovascular system and gives physicians crucial time for diagnosis and therapy. Xenios was formed in 2013 when the two German medical technology firms Novalung and Medos merged under a newly created holding company, Xenios AG. Novalung GmbH was fully integrated into Xenios AG at the end of August 2019, and Medos Medizintechnik GmbH was fully integrated in September 2022. The Novalung brand has been retained as an established intensive care market brand and developed further with the support of Fresenius Medical Care. At the end of 2016, Xenios AG became part of Fresenius Medical Care, the world's leading provider of products and services for people with renal diseases. Within Fresenius Medical Care, Xenios operates as the Heart & Lung specialist and is an integral part of the group's critical care strategy to become a leader in extracorporeal multi-organ support. Because human organs are a mutually linked system, Fresenius Medical Care pursues a multi-organ support approach in critical care, drawing on its expertise in extracorporeal blood treatment for acute kidney injury; Xenios complements the group's product portfolio in intensive care medicine. Xenios AG has three locations in Germany, with its headquarters in Heilbronn; each site specializes in the production of specific hardware components. Its product offering centers on the Xenios console, a unified platform combining heart and lung support, along with components such as the sensorbox (a compact overview of all connected sensors), the DP3 pump drive with battery-driven backup pump drive, and a gas blender with oxygen monitor. The company's Novalung system received US FDA clearance in 2020 with class II approval, making it the first complete system approved for ECMO therapy and long-term use for a duration of more than six hours. In 2021, Xenios AG received approval from China's National Medical Products Administration (NMPA) for the Xenios console and patient kits for ECMO therapy. Xenios positions itself around a mission of "creating a future worth living" for patients worldwide every day, and its products are not cleared or available for sale in all countries; country-specific regulations apply. The company also maintains compliance disclosures, including the U.S. Sunshine Act and France's Loi Bertrand, and publishes a Code of Conduct covering its holding and single companies or therapy brands.

Xenios AG traces its origins to the merger of two German medical technology companies, Novalung and Medos. In 2013, Novalung and Medos merged with the formation of a holding company, Xenios AG. The new entity was headquartered in Heilbronn, Baden-Wuerttemberg, and focused on extracorporeal heart and lung support technologies. At the end of 2016, Xenios AG became part of Fresenius Medical Care, the world's leading provider of products and services for people with chronic kidney failure. This acquisition placed Xenios within a larger group pursuing a multi-organ support approach in critical care, complementing Fresenius Medical Care's expertise in extracorporeal blood treatment for acute kidney injury. In 2019, the integration of the founding businesses continued: at the end of August 2019, Novalung GmbH became fully integrated within Xenios AG. The Novalung brand was retained as an established brand in the intensive care market and developed further with the support of Fresenius Medical Care as a key pillar in the area of multi-organ support. In 2020, the Novalung system received US FDA clearance. With class II approval, the Novalung system became the first complete system approved for ECMO therapy and long-term use for a duration of more than six hours. In 2021, Xenios AG received approval from China's National Medical Products Administration (NMPA) for the Xenios console and patient kits for ECMO therapy, opening access to the Chinese market. In September 2022, Medos Medizintechnik GmbH became fully integrated within Xenios AG, completing the consolidation of the original merger partners under the Xenios umbrella. Throughout this period, Xenios AG operated three locations in Germany, with its headquarters in Heilbronn, each site specializing in the production of specific hardware components. The company continued to position itself as Fresenius Medical Care's Heart & Lung specialist and an integral part of FME's critical care strategy to become a leader in extracorporeal multi-organ support.

• 2022

  In September 2022, Medos Medizintechnik GmbH became fully integrated within Xenios AG.

• 2021

  Xenios AG receives approval from China's NMPA for the Xenios console and patient kits for ECMO therapy.

• 2020

  Novalung system receives US FDA clearance with class II approval, the first complete system approved for ECMO therapy and long-term use for more than six hours.

• 2019

  End of August 2019, Novalung GmbH became fully integrated within Xenios AG.

• 2016

  End of 2016, Xenios AG became a part of Fresenius Medical Care.

• 2013

  Novalung and Medos merge with the formation of a holding company, Xenios AG.

Specialist in extracorporeal heart and lung support (ECMO/ECLS) within Fresenius Medical Care's critical care multi-organ support strategy.

• Xenios console

  A single technological platform combining both cardiac and pulmonary support; supports gas exchange in the lungs and the cardiovascular system.

• Sensorbox

  Provides a compact overview of all connected sensors and represents an essential component of the console hardware.

• DP3 pump drive

  Pump drive and battery-driven backup pump drive.

• Gas blender with oxygen monitor

  Two different gas blending options with oxygen monitoring.

• Novalung system

  First complete system approved for ECMO therapy and long-term use for a duration of more than six hours (US FDA class II clearance, 2020).

1. 1Xenios AG | Specialist for ECMO treatmentxenios-ag.com
2. 2Xenios AG is specialized in extracorporeal heart and lung supportxenios-ag.com
3. 3About us - Xenios AGxenios-ag.com
4. 4Xenios AG (Germany) - Wikidatawikidata.org